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Background: Small-cell lung cancer with epidermal growth factor receptor (EGFR) gene mutation typically
manifests as a transformation occurring after EGFR tyrosine kinase inhibitor therapy for adenocarcinoma with EGFR
mutation, whereas primary small-cell lung cancer showing EGFR mutation is extremely rare. Second biopsy of
EGFR-mutated tumor has been broadly recognized as necessary, but is not always performed in daily practice,
mainly due to the imbalance between the potential risk of the diagnostic procedure and the therapeutic impact of
the biopsy result.
Case presentation: A 70-year-old woman who had never smoked was referred to our hospital with chief
complaints of cough and back pain. Transbronchial lung biopsy from the primary tumor of the left upper lobe
revealed combined small-cell lung cancer and adenocarcinoma, a subtype of small-cell lung cancer. EGFR L861Q
mutation was detected in both small-cell lung cancer and adenocarcinoma components. Given the staging of
cT2aN3M1b (Stage IV) and histological diagnosis, first-line chemotherapy with cisplatin plus irinotecan was initiated,
and partial response was achieved. Seven months after initial diagnosis, the primary tumor enlarged again, and a
second biopsy from the enlarged lesion detected only adenocarcinoma with the L861Q mutation. Erlotinib was
started, but multiple brain metastases and enlarged mediastinal lymph nodes subsequently appeared. Whole-brain
radiation therapy was performed, and endobronchial ultrasonography-guided transbronchial biopsy from the lymph
node revealed reverse transformation to small-cell lung cancer with the L861Q mutation. Amrubicin therapy
achieved partial response after two cycles, with the shrinkage lasting for eight months. Serum sialyl Lewis X antigen
level increased when the adenocarcinoma component was dominant, whereas plasma pro-gastrin-releasing peptide
level increased when the small-cell lung cancer component became dominant.
Conclusions: Transformation of the tumor correlates with the difference between small-cell lung cancer and
adenocarcinoma in sensitivity to therapies, so repeated biopsies are beneficial for choosing appropriate treatments.
Noninvasively obtainable parameters such as tumor markers can support the need for biopsy.
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Epidermal growth factor receptor (EGFR) gene mutation
is one of the most pervasive driver mutations in non-
small cell lung cancer (NSCLC), particularly in adeno-
carcinoma [1]. Activating mutations in EGFR occur in
exons 18 to 21, and most of the mutations in exons 18,
19 and 21 are regarded as sensitizing mutations for
EGFR tyrosine kinase inhibitors (TKIs) [2]. Of these,
exon 19 deletions and the exon 21 L858R point muta-
tion account for more than 80% of mutations detected
in tumors with EGFR mutations [2,3]. EGFR-TKI ther-
apy for NSCLC with an EGFR mutation shows a signifi-
cantly higher response rate, longer progression-free
survival, and better quality of life when compared with
platinum-doublet chemotherapy [4,5]. First-line treat-
ment with EGFR-TKI is thus recommended for EGFR
mutation-bearing NSCLC in recent clinical practice
guidelines [6,7]. In contrast, EGFR mutation is rarely de-
tected in small-cell lung cancer (SCLC). EGFR mutations
in SCLC mostly manifest as a “transformation” after
EGFR-TKI therapy in EGFR-mutated adenocarcinoma
[8], whereas primary SCLC with EGFR mutation is ex-
tremely rare. Some case reports have described EGFR-
mutated SCLC treated using EGFR-TKI, but responses
to EGFR-TKI differ [9,10]. To date, whether EGFR-TKIs
or cytotoxic chemotherapy should be administered forFigure 1 Computed tomography at the time of initial diagnosis. A) Pr
B) Enlargement of the mediastinal lymph nodes. C) Left pleural disseminatSCLC with an EGFR mutation remains unclear. A case
of SCLC with a rare EGFR mutation that showed “wax-
and-wane” transformation is presented, and EGFR muta-
tions in SCLC are comprehensively reviewed.
Case presentation
A 70-year-old Japanese woman was referred to our hos-
pital with chief complaints of cough and back pain. She
had never smoked and had no history of malignancy.
Computed tomography (CT) revealed a 4-cm-diameter
mass in the left upper lobe, enlargement of mediastinal
lymph nodes, and left pleural dissemination (Figure 1).
Asymptomatic brain metastasis was also detected on
magnetic resonance imaging. A transbronchial lung bi-
opsy (TBLB) specimen from the left upper lobe showed
combined SCLC and adenocarcinoma (Figure 2), and
the TNM classification of the tumor was cT2aN3M1b
(BRA). The TBLB specimens were analyzed using a pep-
tide nucleic acid-locked nucleic acid PCR clamp test,
and EGFR exon 21 L861Q mutations were detected in
both SCLC and adenocarcinoma components (Figure 3).
The patient underwent four cycles of chemotherapy com-
prising cisplatin (60 mg/m2) and irinotecan (60 mg/m2).
The total effect of chemotherapy was partial response, and
symptoms resolved. Serum sialyl Lewis X antigen (SLX)
level decreased from 35 U/mL at the initiation ofimary lung cancer lesion in the upper lobe of the left lung.
ion.
Figure 2 Histopathology of combined small-cell lung cancer.
A) Transbronchial lung biopsy from the primary lesion shows
adenocarcinoma (hematoxylin and eosin staining, marked with
arrow). The insets show that this tumor is positive for TTF-1 and
negative for synaptophysin and chromogranin. B) Another slice from
the same biopsy specimen shows small-cell lung cancer
(hematoxylin and eosin staining, marked with arrow). The insets
show that this tumor is positive for TTF-1, synaptophysin, and chro-
mogranin. chr, chromogranin; syn, synaptophysin; TTF, TTF-1.
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apy, and plasma levels of pro-gastrin releasing peptide (pro-
GRP) also decreased from 695 pg/mL to 102 pg/mL.
Complete remission of the brain metastasis was also
achieved, and whole-brain radiation therapy (WBRT) was
postponed at the request of the patient.
Seven months after initial diagnosis, disease progres-
sion with enlargement of the primary tumor and lymph
nodes was observed. Serum SLX level was elevated to 14
U/mL, while plasma pro-GRP level remained stable
(102 pg/mL). TBLB of the primary tumor was performed
again, and only adenocarcinoma with the EGFR L861Q
mutation was detected (Figure 3). Treatment with erloti-
nib (150 mg daily) was thus started.
After two months of disease stabilization, multiple brain
metastases developed without any symptoms. The patient
underwent WBRT of 30 Gy. Soon after the completion of
WBRT, mediastinal lymph node enlargement occurred
again. Serum SLX level was decreased (9.1 U/mL),
but plasma pro-GRP level increased to 133 pg/mL.Endobronchial ultrasonography-guided transbronchial bi-
opsy was performed. At that time, only SCLC with the
EGFR L861Q mutation was identified (Figure 3). PIK3CA
mutation analysis of the second (adenocarcinoma) and third
(SCLC) biopsy specimens was performed, but no mutation
was detected from either sample. Erlotinib was stopped, and
chemotherapy with amrubicin (35 mg/m2) achieved partial
response after two cycles. This treatment was therefore
continued for nine cycles without disease progression.
SLX and pro-GRP levels both decreased, to <2.5 U/mL and
79.8 pg/mL, respectively. However, chemotherapy was ter-
minated when performance status decreased after lumbar
vertebral compression without bone metastasis. Chemother-
apy was then terminated. The patient remains alive as of
21 months after diagnosis.Conclusions
Few case reports have described primary EGFR-mutated
adenocarcinoma transforming to SCLC and then reverse-
transforming to adenocarcinoma [8,11]. As far as we can de-
termine, this represents the first report of initially diagnosed
SCLC with an EGFR mutation that showed transformations
in both directions. EGFR L861Q mutation was detected
from all specimens obtained on each occasion. Taking the
rarity of L861Q mutation among EGFR activating mutations
[2] into account, it appears very likely that both the SCLC
and adenocarcinoma components shared a common origin.
Relatively good response to cytotoxic chemotherapy was ob-
served throughout the course of treatment. Tumor markers
such as SLX and pro-GRP reflected the pathological changes
in the tumor.
Although the objective response to erlotinib therapy was
modest, the dominant component of the tumor in the
present case changed from adenocarcinoma to SCLC after
EGFR-TKI therapy. Generally, histological examination of
TBLB specimens can provide the histology of only a part of
the disease, but all biopsies were performed from enlarging
lesions, reflecting the dominant component of the progres-
sing disease. We suggest that responsiveness to EGFR-TKI
varies between SCLC and adenocarcinoma, and the SCLC
component that did not respond to erlotinib progressed se-
lectively. In a similar manner, most cases of SCLC with
EGFR mutations have been reported as developing acquired
resistance to EGFR-TKI, and were initially diagnosed as
NSCLC [8,11-15]. In general, lung adenocarcinoma and
SCLC show different genetic characteristics [15,16]. In
mouse models, concomitant knockout of Rb and p53 causes
a high incidence of SCLC, whereas mice with somatic inacti-
vation of p53 alone develop adenocarcinomas [17]. A previ-
ous study showed an acquired PIK3CA mutation in SCLC
transformed from EGFR-mutated adenocarcinoma after
EGFR-TKI therapy [8]. Unfortunately, it was not possible to
detect concomitant molecular alterations in the present
Figure 3 EGFR L861Q amplification curve for each specimen by the peptide nucleic acid-locked nucleic acid PCR clamp test. A) Small-
cell lung cancer component of the specimen at the time of initial diagnosis. B) Adenocarcinoma component of the specimen at the time of initial
diagnosis. C) Adenocarcinoma at the time of disease progression after cisplatin-irinotecan therapy. D) Small-cell lung cancer at the time of disease
progression after erlotinib therapy.
Table 1 Small-cell lung cancer with EGFR mutations and treatment outcomes
Prior TKI Mutation Chemotherapy PFS Hist after Tx Ref.
None L861Q CDDP + CPT-11 7 mo Adenocarcinoma *
E L861Q AMR 8 mo N/A *
None G719A G N/A (PR) N/A [9]
None Ex19del CRT 7 mo N/A [10]
None Ex19del CDDP + VP-16 6 mo N/A [10]
G Ex19del G 5 mo N/A [18]
G, E Ex19del G + VP-16 N/A (PD) N/A [12]
G Ex19del CDDP + CPT-11 6 mo Adenocarcinoma [11]
G, E L858R TOP >4 mo (CR) N/A [13]
E L858R CRT 6 mo Adenocarcinoma [8]
E L858R CDDP + VP-16 N/A (PR) N/A [8]
G L858R CDDP + VP-16 N/A (PR) N/A [14]
Reports without sufficient information about treatment are not included on this table.
*, present case; AMR, Amrubicin; CDDP, Cisplatin; CPT-11, Irinotecan; CR, Complete response; CRT, Combined chemoradiotherapy; E, Erlotinib; Ex19del, Exon 19
deletions; G, Gefitinib; Hist after Tx, Histology after treatment; mo, Months; N/A, Not assessed; PFS, Progression-free survival; PR, Partial response; Ref., Reference;
TKI, Epidermal growth factor receptor tyrosine kinase inhibitor; TOP, Topotecan; VP-16, Etoposide.
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sistance to EGFR-TKI in EGFR-mutated SCLC.
SCLC with an EGFR mutation is often resistant to
EGFR-TKI, as mentioned above, whereas most cytotoxic
chemotherapies achieve good response (Table 1). Second
biopsy after cytotoxic chemotherapy for SCLC with an
EGFR mutation revealed transformation to adenocarcin-
oma in various reports [8,11], indicating that the SCLC
component is more sensitive to cytotoxic chemotherapy
than the adenocarcinoma component. The differences in
effectiveness of therapeutic regimens between histo-
logical types strongly support the indication of repeated
biopsies at the time of each treatment change.
In this case, transitions in tumor markers (SLX and
pro-GRP) appeared to occur in parallel with histological
transformation. Second biopsy has been broadly recog-
nized as necessary [8], but has not always been carried
out in daily practice. This is mainly attributable to the
imbalance between the potential risk of the diagnostic
procedure and the therapeutic impact of the biopsy re-
sult. Given the sensitivity of EGFR-mutated SCLC to
cytotoxic chemotherapies, re-biopsy for detecting tumor
transformation can prove highly beneficial for patients.
Noninvasive methods, including tumor markers, circu-
lating tumor cells [19], and highly sensitive mutation de-
tection using plasma samples [20] may play an
important role in guiding the decisions of physicians and
patients for the next diagnostic step, particularly when
an invasive procedure is needed for obtaining tumor
samples.
In conclusion, the optimal regimen for SCLC with an
EGFR mutation cannot be uniformly defined, and should
be decided according to the dominant histology at each
point in the treatment course. Repeated biopsies are some-
times difficult in daily practice, but noninvasively obtainable
parameters such as tumor markers can support the need
for diagnostic procedures. Detailed examination of com-
bined SCLC and adenocarcinoma, including comprehen-
sive genome analysis, may reveal the factors that determine
the histological and clinical characteristics of these tumors.Ethics statement
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